Literature DB >> 7823972

Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I.

H P Hartung1, J D Pollard, G K Harvey, K V Toyka.   

Abstract

The etiology of the Guillain-Barré syndrome (GBS) still remains elusive. Recent years have witnessed important advances in the delineation of the mechanisms that may operate to produce nerve damage. Evidence gathered from cell biology, immunology, and immunopathology studies in patients with GBS and animals with experimental autoimmune neuritis (EAN) indicate that GBS results from aberrant immune responses against components of peripheral nerve. Autoreactive T lymphocytes specific for the myelin antigens P0 and P2 and circulating antibodies to these antigens and various glycoproteins and glycolipids have been identified but their pathogenic role remains unclear. The multiplicity of these factors and the involvement of several antigen nonspecific proinflammatory mechanisms suggest that a complex interaction of immune pathways results in nerve damage. Data on disturbed humoral immunity with particular emphasis on glycolipid antibodies and on activation of autoreactive T lymphocytes and macrophages will be reviewed. Possible mechanisms underlying initiation of peripheral nerve-directed immune responses will be discussed with particular emphasis on the recently highlighted association with Campylobacter jejuni infection.

Entities:  

Mesh:

Year:  1995        PMID: 7823972     DOI: 10.1002/mus.880180202

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  25 in total

1.  Transfer of myelin-specific cells deviated in vitro towards IL-4 production ameliorates ongoing experimental allergic neuritis.

Authors:  C Ekerfelt; C Dahle; R Weissert; M Kvarnström; T Olsson; J Ernerudh
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

2.  A case of Guillain-Barré syndrome associated with cerebellar ataxia and positive serum anti-GD1b IgG antibody.

Authors:  Hideki Sugimoto; Nobuo Wakata; Masahiko Kishi; Toshiki Fujioka; Teruyuki Kurihara; Yukiko Irie; Toyokazu Saito
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

3.  Detection of serious bradyarrhythmias in Guillain-Barré syndrome: sensitivity and specificity of the 24-hour heart rate power spectrum.

Authors:  P Flachenecker; K Lem; W Müllges; K Reiners
Journal:  Clin Auton Res       Date:  2000-08       Impact factor: 4.435

4.  Cdc42 GTPases facilitate TNF-α-mediated secretion of CCL2 from peripheral nerve microvascular endoneurial endothelial cells.

Authors:  Kelly A Langert; Cynthia L Von Zee; Evan B Stubbs
Journal:  J Peripher Nerv Syst       Date:  2013-09       Impact factor: 3.494

5.  Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome.

Authors:  E Sindern; K Schweppe; L M Ossege; J P Malin
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

6.  Anti-ganglioside antibodies alter presynaptic release and calcium influx.

Authors:  Brigitte Buchwald; Gang Zhang; Angela K Vogt-Eisele; Weiyi Zhang; Raheleh Ahangari; John W Griffin; Hanns Hatt; Klaus V Toyka; Kazim A Sheikh
Journal:  Neurobiol Dis       Date:  2007-07-14       Impact factor: 5.996

Review 7.  Multifocal motor neuropathy.

Authors:  E Nobile-Orazio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 8.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

9.  Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses.

Authors:  J Zhu; X F Bai; G Hedlund; J Björk; M Bakhiet; P H Van Der Meide; H Link
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 10.  [Autoimmune neuropathies--current aspects of immunopathologic diagnostics and therapy].

Authors:  R Gold; A Bayas; K V Toyka
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.